Journal of Immunology Research

Research Article

Immunological Evaluation and Comparison of Different EV71 Vaccine Candidates

Table 1

Summary of mouse immunogenicity studies with different EV71 vaccine candidates.
EV71 vaccine candidates Adjuvant formulated Total IgG titers Western blot Virus neutralization titer
VP1-43VP2-28rVP1rVP2rVP3EV71 (B4 E59)CVA16 (N5079)
VP1-43Alum 1/3200  ++  <1/8<1/8
VP1-43CFA/IFA 1/6400 +++   1/32<1/8
VP2-28Alum  1/200  −  <1/8 <1/8
VP2-28CFA/IFA  1/1600  + <1/8<1/8
VP1-43/VP2-28 CFA/IFA 1/6400 1/800+++ +   1/32 <1/8
rVP1Alum 1/6400  +++   <1/8 <1/8
rVP1CFA/IFA 1/12800  +++   1/128<1/8
rVP2Alum  <1/100  +++   <1/8 <1/8
rVP2 CFA/IFA  1/200  +++  1/8 <1/8
rVP3 Alum     ++<1/8 <1/8
rVP3 CFA/IFA      +++ 1/8 <1/8
EV71-VLPPBS 1/1600 <1/100 ++ ++++ 1/64 <1/8
EV71-VLP Alum1/6400 <1/100 ++ ++ ++ 1/128 <1/8
EV71-VLP CFA/IFA1/12800 <1/100 +++ +++ ++ 1/160 <1/8
2 μg of inactivated         
 EV71 virion PBS 1/6400 <1/100 ++++++ ++ 1/64 <1/8
 EV71 virion Alum 1/12800 <1/100 +++ +++ ++ 1/640 <1/8
5 μg of inactivated        
 EV71 virion Alum 1/12800 <1/100 +++ +++ +++1/2560 <1/8
Three to six mice per group were immunized 3 times with EV71 vaccine candidates formulated with alum or CFA/IFA. Fifty micrograms of synthetic peptides, 20 μg of recombinant EV71 viral structural proteins, and 5 μg of recombinant virus-like particles (EV71-VLP) were used in the mouse immunogenicity studies. The protocols for IgG titer determination, western blot analysis, and virus neutralization assay are described in Section 2.